The PDCD4/miR-21 pathway in medullary thyroid carcinoma

Human Pathology

Volumn 46, Issue 1, 2015, Pages 50-57

  Pennelli, Gianmaria ^a   Galuppini, Francesca ^a   Barollo, Susi ^a   Cavedon, Elisabetta ^a   Bertazza, Loris ^a   Fassan, Matteo ^b   Guzzardo, Vincenza ^a   Pelizzo, Maria Rosa ^a   Rugge, Massimo ^a,c   Mian, Caterina ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Akt; Immunohistochemistry; Medullary thyroid cancer; MiR 21; PDCD4

Indexed keywords

CALCITONIN; KI 67 ANTIGEN; MICRORNA 21; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED CELL DEATH 4; PROTEIN KINASE B; PROTEIN RET; RAS PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; MICRORNA; MIRN21 MICRORNA, HUMAN; PDCD4 PROTEIN, HUMAN; RET PROTEIN, HUMAN; RNA BINDING PROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOMATION; CALCITONIN BLOOD LEVEL; CHILD; CODON; CONTROLLED STUDY; DOWN REGULATION; EXON; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; NUCLEOTIDE SEQUENCE; PDCD4 GENE; POINT MUTATION; PRESCHOOL CHILD; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SCHOOL CHILD; THYROID MEDULLARY CARCINOMA; TUMOR SUPPRESSOR GENE; UPREGULATION; VERY ELDERLY; WESTERN BLOTTING; WILD TYPE; BIOPSY; BLOOD; CANCER STAGING; CHEMISTRY; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; MORTALITY; MUTATION; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; THYROID TUMOR; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; BIOPSY; CALCITONIN; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MICRORNAS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHENOTYPE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RET; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; YOUNG ADULT;

EID: 84915748509     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.09.006     Document Type: Article

References (42)

1. M.R. Young, A.N. Santhanam, and N. Yoshikawa Have tumor suppressor PDCD4 and its counteragent oncogenic miR-21 gone rogue? Mol Interv 10 2010 76 79
2. H. Allgayer Pdcd4, a colon cancer prognostic that is regulated by a microRNA Crit Rev Oncol Hematol 73 2010 185 191
3. U. Liwak, N. Thakor, and L.E. Jordan Tumor suppressor PDCD4 represses internal ribosome entry site-mediated translation of antiapoptotic proteins and is regulated by S6 kinase 2 Mol Cell Biol 32 2012 1818 1829
4. M.D. Dennis, L.S. Jefferson, and S.R. Kimball Role of p70S6K1-mediated phosphorylation of eIF4B and PDCD4 proteins in the regulation of protein synthesis J Biol Chem 287 2012 42890 42899
5. M. Fassan, M. Pizzi, and G. Battaglia Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis J Clin Pathol 63 2010 692 696
6. M. Fassan, M. Pizzi, and L. Giacomelli PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis Virchows Arch 485 2011 413 419
7. M. Fassan, S. Realdon, and M. Pizzi Programmed cell death 4 nuclear loss and miR-21 or activated Akt overexpression in esophageal squamous cell carcinogenesis Dis Esophagus 25 2012 263 268
8. M. Yasuda, T. Schmid, and D. Rübsamen Downregulation of programmed cell death 4 by inflammatory conditions contributes to the generation of the tumor promoting microenvironment Mol Carcinog 49 2010 837 848
9. L.B. Frankel, N.R. Christoffersen, and A. Jacobsen Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells J Biol Chem 283 2008 1026 1033
10. F.J. Sheedy, E. Palsson-McDermott, and E.J. Hennessy Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21 Nat Immunol 11 2009 141 147
11. H.S. Yang, A.P. Jansen, and R. Nair A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NFkappaB or ODC transactivation Oncogene 21 2001 669 676
12. S. Barollo, R. Pezzani, and A. Cristiani Functional significance of the novel H-RAS gene mutation M72I in a patient with medullary thyroid cancer Exp Clin Endocrinol Diabetes 131 2013 546 550
13. S. Leboulleux, E. Baudin, J. Travagli, and M. Schlumberger Medullary thyroid carcinoma Clin Endocrinol 61 2004 299 310
14. H.A. Sheikh, M. Tometsko, and L. Niehouse Molecular genotyping of medullary thyroid carcinoma can predict tumor recurrence Am J Surg Pathol 18 2004 101 106
15. R.T. Kloos, C. Eng, and D.B. Evans Medullary thyroid cancer: management guidelines of the American Thyroid Association Thyroid 19 2009 565 612
16. K. Frank-Raue, S. Rondot, and F. Raue Molecular genetics and phenomics of RET mutations: impact on prognosis of MTC Mol Cell Endocrinol 30 2010 2 7
17. C. Mian, G. Pennelli, and S. Barollo Combined ret and ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification Eur J Endocrinol 6 2011 971 976
18. D. Abraham, N.E. Jackson, and J.S. Gundara MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis and potential therapeutic targets Clin Cancer Res 17 2011 4772 4781
19. M.N. Nikiforova, G.C. Tseng, D. Steward, D. Diorio, and Y.E. Nikiforov MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility J Clin Endocrinol Metab 93 2008 1600 1608
20. J. Hudson, E. Duncavage, and A. Tamburrina Overexpression of miR-10a and miR-375 and downregulation of YAP1in medullary thyroid carcinoma Exp Mol Pathol 95 2013 62 67
21. L. Santarpia, G.A. Calin, and L. Adam A miRNA signature associated with human metastatic medullary thyroid carcinoma Endocr Relat Cancer 20 2013 809 823
22. C. Mian, G. Pennelli, and M. Fassan MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome Thyroid 22 2012 890 896
23. G. Pennelli, F. Vianello, and S. Barollo BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma Thyroid 21 2011 1393 1396
24. M. Fassan, M. Cagol, and G. Pennelli Programmed cell death 4 (PDCD4) protein in esophageal cancer Oncol Rep 24 2010 135 139
25. M. Rugge, M. Fassan, and R. Clemente Bronchopulmonary carcinoid: phenotype and long-term outcome in a single institution series of Italian patients Clin Cancer Res 14 2008 149 154
26. G. Pennelli, M. Fassan, and C. Mian PDCD4 expression in thyroid neoplasia Virchows Arch 462 2013 95 100
27. S. Barollo, R. Pezzani, and A. Cristiani Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations Thyroid 24 2014 809 819
28. J. Lu, G. Getz, and E.A. Miska MicroRNA expression profiles classify human cancers Nature 435 2005 834 838
29. C.M. Croce Causes and consequences of microRNA dysregulation in cancer Nat Rev Genet 10 2009 704 714
30. P. Pallante, R. Visone, and C.M. Croce Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas Endocr Relat Cancer 17 2010 91 104
31. C.K. Chou, R.F. Chen, and F.F. Chou miR-146b is highly expressed in adult papillary thyroid carcinomas with high-risk features including extrathyroidal invasion and the BRAF(V600E) mutation Thyroid 20 2010 489 494
32. D. Frezzetti, M. De Menna, and P. Zoppoli Upregulation of miR-21 by Ras in vivo and its role in tumor growth Oncogene 30 2011 275 286
33. A. Palamarchuk, A. Efanov, V. Maximov, R.I. Aqueilan, C.M. Croce, and Y. Pekarsky Akt phosphorylates and regulates Pdcd4 tumor suppressor protein Cancer Res 64 2005 11282 11286
34. G. Mudduluru, F. Medved, and R. Grobholz Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer Cancer 110 2007 1697 1707
35. H. Si, X. Sun, and Y. Chen Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer J Cancer Res Clin Oncol 139 2013 223 229
36. D. Tang, Y. Shen, and M. Wang Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer Eur J Cancer Prev 22 2013 540 548
37. Q. Wang, P. Li, and A. Li Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma J Exp Clin Cancer Res 104 2012 847 851
38. Y. Wang, X. Gao, and F. Wei Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis Gene 533 2014 389 397
39. C.H. Yang, J. Yue, M. Sims, and L.M. Pfeffer The curcumine analog EF24 targets NF-kB and miRNA-21, and has potent anticancer activity in vitro and in vivo PLoS One 8 2013 e71130
40. X. Zhou, Y. Ren, and A. Liu STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo Oncol Rep 31 2014 2173 2180
41. W. Ren, X. Wang, and L. Gao MIR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4 Mol Cell Biochem 390 2014 253 262
42. W.H. Paik, H.R. Kim, and J.K. Park Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol Anticancer Res 33 2013 1473 1481